日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Customizable virus-like particles deliver CRISPR-Cas9 ribonucleoprotein for effective ocular neovascular and Huntington's disease gene therapy.

可定制的病毒样颗粒递送 CRISPR-Cas9 核糖核蛋白,用于有效的眼部新生血管和亨廷顿病基因治疗

Ling Sikai, Zhang Xue, Dai Yao, Jiang Zhuofan, Zhou Xujiao, Lu Sicong, Qian Xiaoqing, Liu Jianping, Selfjord Niklas, Satir Tugce Munise, Lundin Anders, Touza Julia Liz, Firth Mike, Van Zuydam Natalie, Bilican Bilada, Akcakaya Pinar, Hong Jiaxu, Cai Yujia

Preclinical efficacy and safety evaluation of BD211 autologous CD34(+) hematopoietic stem cell injection for transfusion-dependent β-thalassemia in NCG-X mice

在NCG-X小鼠中,对BD211自体CD34(+)造血干细胞注射治疗输血依赖型β-地中海贫血的临床前疗效和安全性进行了评估。

Dai, Xuedong; Li, Zike; Chen, Shuang; Huang, Ying; Ling, Sikai; Wang, Quanjun; Wang, Qi

In vivo CRISPR gene editing in patients with herpetic stromal keratitis.

在疱疹性基质性角膜炎患者中进行体内 CRISPR 基因编辑

Wei Anji, Yin Di, Zhai Zimeng, Ling Sikai, Le Huangying, Tian Lijia, Xu Jianjiang, Paludan Soren R, Cai Yujia, Hong Jiaxu